Podcasts about gliomas

Neurologist Michelle Monje studies the close relationship between cancer and the nervous system, particularly in an aggressive brain cancer that often strikes in childhood. Her research shows that the cancer cells are electrically integrated into the brain itself and these connections actually help the cancer to grow. Monje and collaborators have now developed an immunotherapy that has shown great promise in mice and early human trials. One patient had a “complete response” and is cancer-free four years after treatment, Monje tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Michelle MonjeConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michelle Monje, a professor of pediatric neurology at Stanford University.(00:03:39) Focus on Cancer ResearchMonje's clinical observations led to exploring cancer-neuron interactions.(00:05:28) Neurons and Glial CellsThe role of neurons and glial cells in brain function and disease.(00:08:32) Gliomas in ChildrenAn overview of gliomas and their origins in glial precursor cells.(00:10:12) Rethinking Brain Cancer BehaviorHow gliomas don't just grow—they integrate with brain circuits.(00:14:49) Mechanisms of Tumor GrowthTwo primary mechanisms by which cancer exploits the nervous system.(00:16:32) Synaptic Integration of Cancer CellsThe discovery that glioma cells form synapses with neurons.(00:20:06) CAR T-Cell TherapyAdapting CAR T-cell immunotherapy to target brain tumors.(00:22:52) Targeting GD2 AntigenIdentification of a surface marker enables precision CAR T-cell therapy.(00:24:35) Immune Access to the BrainThe ability of CAR T-cells to reach the brain, despite prior understanding.(00:26:16) First Clinical Trial ResultsThe significant tumor reduction and response from CAR T-cell therapy.(00:28:21) Combined TherapiesPairing immune therapy with neural signaling blockers for better outcomes.(00:30:35) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Which patients with IDH-mutant glioma should receive an isocitrate dehydrogenase (IDH) inhibitor? A top neurosurgeon weighs in. Credit available for this activity expires: 6/9/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002598?ecd=bdc_podcast_libsyn_mscpedu

Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

Radiation therapy or radiotherapy, is a common treatment for cancer, but its effectiveness differs across patients. A recent study published as the cover for Volume 17, Issue 2 of Aging explored why this happens. The findings provide valuable insights, particularly for brain cancers like glioblastoma (GBM) and low-grade gliomas (LGG). Understanding Glioblastoma and Low-Grade Gliomas Glioblastoma and LGG are both brain tumors, but they behave in very different ways. GBM is highly aggressive, with most patients surviving only 12 to 18 months, even with surgery, chemotherapy, and radiation therapy. LGG, on the other hand, grows more slowly, and many patients live for decades with proper care. Despite their differences, LGG and GBM are biologically linked. Some LGG tumors eventually transform into GBM, making early treatment decisions critical. Given radiation therapy's effectiveness in GBM, it has often been assumed that LGG patients would also benefit from it. However, a new study titled “Variability in radiotherapy outcomes across cancer types: a comparative study of glioblastoma multiforme and low-grade gliomas” challenges this assumption. Full blog - https://aging-us.org/2025/03/how-radiation-therapy-affects-tumors-glioblastoma-vs-low-grade-gliomas/ Paper DOI - https://doi.org/10.18632/aging.206212 Corresponding author - Morten Scheibye-Knudsen - mscheibye@sund.ku.dk Video short - https://www.youtube.com/watch?v=j91rzDJHXTE Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206212 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cancer, biomarkers, radiotherapy, GBM, LGG, survival About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes “Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies.” by Dr. Ludmila Papusha et al. published on July 08, 2024. TRANSCRIPT  Jiasen He: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host Jiasen He, a JCO Journal's Editorial Fellow. Today, I will provide a summary on “Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies.” This is an observational study by Dr. Ludmila Papusha and colleagues that investigated the use of target therapies in early childhood with midline low grade glioma. Low grade glioma located in the hypothalamic chiasmatic region, thalamus and the brain stem are classified as midline low grade gliomas. Due to their unique locations, complete surgical resection is usually not able to be achieved. In young children with low grade glioma, radiation therapy is generally not favored. Traditionally, chemotherapy regimens such as carboplatin and vincristine have been used. However, as Dr. Papusha noted, this population often exhibits poor response to chemotherapy. With a growing understanding of the RAS-RAF-MEK pathways in low grade glioma, targeted therapy has emerged as a promising treatment option for this group. However, limited data is available regarding the mutation status of midline low grade glioma in early childhood and real world evidence on their response to targeted therapy remains scarce. Dr. Papusha's research aimed to address this critical gap by evaluating the effectiveness of targeted therapy in midline gliomas of early childhood. In this observational study, 40 patients under the age of three with midline low grade glioma were enrolled. Somatic genetic aberrations associated with activation of RAS-RAF signaling pathway were identified in 95% of the cohort with BRAF fusion being the most common aberration followed by the BRAF V600E mutation. These findings confirm the presence of targetable mutations in this specific population and provide a foundation for the use of targeted therapy. Diencephalic syndrome is a rare neurologic disorder typically affecting infants and young children with tumors located in the diencephalon. In this cohort, 43% of the optic pathway and hypothalamic gliomas manifested diencephalic syndrome. Among 30 patients who received first line chemotherapy, primary carboplatin and vincristine, the two-year and five-year progression-free survival rate were only 24% and 6.4% respectively, indicating that most patients experience disease progression with chemotherapy. Targeted therapy was administered to 27 patients of whom 22 experienced disease progression during or after chemotherapy. A total of 26 patients were available for evaluation. Dr. Papusha reported that all patients benefited from targeted therapy with 12 achieving a partial response, 2 showing a minor response and 12 maintaining stable disease. The median duration of targeted therapy was 16 months. These findings demonstrate the efficacy of targeted therapy in this population. Regarding toxicity from targeted therapy in this population, the most common adverse event was grade 1 to 2 skin toxicity observed in 52% of patients. Severe toxicity occurred in 36% of patients treated with trametinib including grade 3 skin toxicity, mucositis and hematuria. Additionally, grade 3 gastrointestinal toxicity was reported. Interestingly, all three patients who experienced grade 3 gastrointestinal toxicity had diencephalic syndrome at the time of targeted therapy initiation. The author also noted cases of disease progression during treatment breaks. However, tumor response was restored in all affected patients upon resumption of targeted therapy. The two-year progression-free survival rate was 59%. In conclusion, Dr. Papusha states the unique characteristics of infantile midline low grade glioma, including the high prevalence of diencephalic syndrome and resistance to chemotherapy. The study contributes valuable information on the targetable mutation profile in this population and provides further evidence supporting the use of targeted therapy while emphasizing the need for low monitoring of severe adverse events. As the author notes, important questions remain regarding the long term side effects of kinase inhibitors in infants and children as well as optimal duration of therapy. Thank you for listening to JCO Precision Oncology Article Insights and please tune in for the next topic. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Katherine Peters, PhD, a neurologist and neurooncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided context on a new analysis from the phase 3 INDIGO trial, a study assessing vorasidenib in patients with mutant isocitrate dehydrogenase (mIDH) 1/2 diffuse gliomas. The conversation, which occurred at the 2024 AAN Annual Meeting, covered the covered the therapeutic potential of this agent and its impacts on quality of life, neurocognition, and seizure control. Peters, an expert in the field, provided insight on the mechanism of action of vorasidenib, the added value behind the exploratory analysis, and the next steps in research. Furthermore, she provided context on the patient sample observed and why these data may hold significant weight going forward.  Looking for more neuromuscular discussion? Check out the NeurologyLive® epilepsy clinical focus page. Episode Breakdown: 1:05 – Mechanism of action of vorasidenib, a mIDH 1/2 inhibitor 2:00 – Overview of exploratory analysis results 4:20 – Significance of new data, how it adds to previous primary and secondary outcomes 5:50 – Neurology News Minute 8:25 – Next steps for the study and use of vorasidenib 10:35 – Remaining unmet needs for patients with diffuse gliomas The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Diazepam Buccal Film's Role in Treating Intermittent Pediatric Seizures, with Michael Rogawski, MD, PhD Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS FDA Approves Sprinkle Formulation of Neurocrine Biosciences' Valbenazine for Tardive Dyskinesia or Huntington disease Chorea Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

The May 2024 replay features four episodes on neuro-oncology for brain cancer awareness month. The episode begins with Dr. Philipp Karschnia discussing the assessment of whether MTHFR polymorphisms affect the risk for leukoencephalopathy. The episode continues with Dr. Ingo Mellinghoff discussing new treatment opinions for isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas. The third interview leads into a conversation with Dr. Linda Liau on the study of vaccine-based therapy for GBM. The episode concludes with Dr. Teddy Totimeh talking about brain tumor programs in Asia and Africa. Podcast Links: MTHFR Polymorphisms and Leukoencephalopathy Risk in CNS Lymphoma Patients   New Treatment for IDH mt Gliomas  Study of Vaccine-Based Therapy for GBM Brain Tumor Programs in Asia and Africa  Article Links: https://doi.org/10.1212/WNL.0000000000207670  https://www.nejm.org/doi/full/10.1056/NEJMoa2304194 https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847 https://doi.org/10.1016/j.wneu.2023.04.067 Disclosures can be found at Neurology.org.

Glioblastoma is the most common malignant brain tumor and one of the most aggressive solid tumors. Much progress has been made in the understanding and classification of gliomas, but progress in terms of prolonging survival has been limited. Several recent investigational therapies are bringing new hope. Our guest today is Dr. Eric Wong from Brown University. He is an international expert on advanced treatments for glioblastoma and a Professor of Medicine, Radiation Oncology, Neurosurgery, and Neurology at Brown University. He was interviewed by Dr. Christoph Stretz, a Vascular and Critical Care neurologist at Brown. Series 5, Episode 6 Featuring: Guest: Dr. Eric Wong, Brown University Interviewer: Dr. Christoph Stretz, Brown University

Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.

BUFFALO, NY- January 30, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.” X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of various human malignancies. However, a comprehensive pan-cancer analysis investigating the prognostic value, immunological functions, and epigenetic associations of XRCC1 remains lacking. In this new study, researchers Guobing Wang, Yunyue Li, Rui Pan, Xisheng Yin, Congchao Jia, Yuchen She, Luling Huang, Guanhu Yang, Hao Chi, and Gang Tian from Southwest Medical University, The Affiliated Hospital of Southwest Medical University, Yibin Hospital of T.C.M, Medical School of Nanchang University, Fourth Military Medical University, and Ohio University aimed to address this knowledge gap by conducting a systematic investigation employing bioinformatics techniques across 33 cancer types. “Our analysis encompassed XRCC1 expression levels, prognostic and diagnostic implications, epigenetic profiles, immune and molecular subtypes, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), immune checkpoints, and immune infiltration, leveraging data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases.” Notably, XRCC1 displayed both positive and negative correlations with prognosis across different tumors. Epigenetic analysis revealed associations between XRCC1 expression and DNA methylation patterns in 10 cancer types, as well as enhanced phosphorylation. Furthermore, XRCC1 expression demonstrated associations with TMB and MSI in the majority of tumors. Interestingly, XRCC1 gene expression exhibited a negative correlation with immune cell infiltration levels, except for a positive correlation with M1 and M2 macrophages and monocytes in most cancers. Additionally, the researchers observed significant correlations between XRCC1 and immune checkpoint gene expression levels. Lastly, their findings implicated XRCC1 in DNA replication and repair processes, shedding light on the precise mechanisms underlying its oncogenic effects. “Overall, our study highlights the potential of XRCC1 as a prognostic and immunological pan-cancer biomarker, thereby offering a novel target for tumor immunotherapy." DOI - https://doi.org/10.18632/aging.205426 Corresponding authors - Guanhu Yang - guanhuyang@gmail.com, Hao Chi - Chihao7511@163.com, and Gang Tian - tiangang@swmu.edu.cn Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, X-ray repair cross-complementation group 1, pan-cancer, prognosis, immune infiltration, tumor microenvironment About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Dr. Iyad Alnahhas interviews Dr. Amanda Saratsis about her recent manuscript entitled: "H3K27M Mutant Glioma: Disease Definition and Biological Underpinnings", published online in Neuro-Oncology in October 2023. Read Paper

Dr. Francis Deng summarizes major highlights of current research and future trends from the September 2023 Neuroradiology Centennial content. Functional MRI in Neuro-Oncology: State of the Art and Future Directions. Pasquini et al. Radiology 2023; 308(3):e222028. Neuroimaging in Dementia: More than Typical Alzheimer Disease. Haller et al. Radiology 2023; 308(3):e230173. MRI of the Brain: What Is Driving Innovation in 2023? Hess. Radiology 2023; 308(3):e231657.  Challenges of Preparing for Diagnostic Radiology Call. Isikbay et al. Radiology 2023; 308(3):e230421. Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy. Branzoli et al. Radiology 2023; 308(3):e223255. Correlating Quantitative MRI-based Apparent Diffusion Coefficient Metrics with 24-month Neurodevelopmental Outcomes in Neonates from the HEAL Trial. Calabrese et al. Radiology 2023; 308(3):e223262.

Today, you'll learn about a tiny device that could have a huge impact on brain cancer, some news about keto and fertility, and the truth about the old saying opposites attract. Microbot Tumor Killer “Microdevices implanted into tumors offer new way to treat brain cancer.” EurekAlert! 2023. “Gliomas.” by Fassil B. Mesfin & Mohammed A. Al-Dhahir. 2023. “Treatment of Adult Gliomas: A Current Update.” by Joo Ho Lee & Chan Woo Wee. 2022. Keto & PCOS “Women with PCOS on keto diet may see improvements in fertility.” EurekAlert! 2023. “Advantages and Disadvantages of the Ketogenic Diet: A Review Article.” by Jennifer T. Batch, et al. 2020. “Polycystic ovary syndrome (PCOS).” Mayo Clinic. 2022. Do Opposites Attract? “Study confirms it: Opposites don't actually attract.” EurekAlert! 2023. “Paula Abdul - Opposites Attract (Official Music Video).” YouTube. 2009. “New academic study links rising income inequality to ‘assortative mating'.” by Rich Morin. 2014. “Evidence of correlations between human partners based on systematic reviews and meta-analyses of 22 traits and UK Biobank Analysis of 133 traits.” by Tanya B. Horwitz, et al. 2023. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

Dr. Iyad Alnahhas interviews Drs. Kelly Hotchkiss and Mustafa Khasraw about their recently published review entitled: "Dendritic cell vaccine trials in gliomas: untangling the lines", published online in Neuro-Oncology in June 2023. Read Paper

Dr. Ingo K. Mellinghoff discusses his paper, "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma". Show references: https://pubmed.ncbi.nlm.nih.gov/37272516/

Dr. Kathryn Nevel talks with Dr. Ingo Mellinghoff about how vorasidenib improved progression-free survival in patients with Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas. Read the related article in The New England Journal of Medicine. Visit NPUb.org/Podcast for associated article links.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.

Description: Dr. Maya Graham interviews Drs. Jasmin Jo, Craig Horbinski and David Schiff about their recent manuscript entitled: "Epidemiology, biology and management of venous thromboembolism in gliomas: an interdisciplinary review", published online in Neuro-Oncology in April 2023. Read Paper

Dr. Ankush Bhatia interviews Dr.François Ducray about his and his team's recent manuscript entitled:"Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study", published online in Neuro-Oncology in March 2023.  

Epileptologist Jessica W. Templer, MD; Neuro-oncologist, Karan S. Dixit, MD; and Neurosurgeon Matthew Tate, MD, PhD, join this episode of the Better Edge podcast to discuss management strategies for patients with low grade glioma. They are members of the Northwestern Medicine Low Grade Glioma Program, which is part of Northwestern Medicine Malnati Brain Tumor Institute.

Concluding their Journey to the Centre of the Brain, Michael and Josh tackle one of the most challenging and difficult cancers in modern oncology: high-grade gliomas. All of the usual suspects are here: irrevocable, progressive disease, limited treatment options and a gulf in evidence so large it makes the Grand Canyon look like a muddy footprint. All in all, not the most optimistic of OftiM episodes, but Josh and Michael will tackle it anyway so you don't have to. And remember: always refer your fit GBM patients to a friendly neighbourhood trials unit near you!Links to studies discussed in this episode (subscription may be required):EORTC 26981-22981 NCIC CE3 (aka the “Stupp study"): https://www.nejm.org/doi/full/10.1056/nejmoa043330RTOG 0825: https://www.nejm.org/doi/full/10.1056/nejmoa1308573Brada et al: https://ascopubs.org/doi/full/10.1200/JCO.2009.27.1932?role=tabTaal et al: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70314-6/fulltextWick et al: https://www.nejm.org/doi/full/10.1056/nejmoa1707358For more episodes, resources and blog posts, visit inquisitiveonc.comFind us on Twitter @InquisitiveOncIf you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comVisit us at your new website www.inquisitiveonc.com for our latest episodes, links to resources and musings!Art courtesy of Taryn SilverMusic courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/Note: This podcast is for educational purposes only. If you are unwell seek medical advice Hosted on Acast. See acast.com/privacy for more information.

Description: Dr. Ankush Bhatia interviews Drs. Julie Miller, Nicolas Gonzalez Castro, Samuel McBrayer and Patrick Wen about their recent manuscript, entitled: "Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions", published online in Neuro-Oncology in October 2022. Full Report

Ashley Ghiaseddin, M.D., highlights treatment strategies for malignant gliomas. He shares challenges to therapeutic options, the standard approaches to treatment, novel treatment strategies and when it is important to refer to the specialists at UF Health Shands Hospital.

Dr. Iyad Alnahhas interviews Drs. Jennifer Cotter and Kee Kiat Yeo about their recent paper entitled: ""Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in pediatrics", published online in Neuro-Oncology in May 2022. Full Article

Gliomas have long been considered one of the most daunting forms of cancer, but advances in research, imaging, and treatments are turning the tide on these brain tumors. Dr. Elizabeth Maher, Director of UT Southwestern's translational research program in neuro-oncology, and Dr. Toral Patel, a neurosurgeon who specializes in advanced surgical techniques, provide a glimpse into the precise and personalized treatment options now available to patients.

WATCH THE VIDEO WEBCAST HERE: https://youtu.be/5TYFsjh91Tw Listen in as our host, Dr. Brenda Weigel from the University of Minnesota, is joined by Dr. Robbie Majzner - an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford University's School of Medicine. Dr. Majzner goes into great detail about his recent clinical trial on GD2-CAR T cell therapy for H3K27M-mutated Diffuse Midline Gliomas - the findings, the process, and what the future holds. You can read more about Dr. Majzner's study here: https://www.nature.com/articles/s41586-022-04489-4 Have any thoughts? Questions? Ideas for future topics? Email us at TWIPO@solvingkidscancer.org. Subscribe to TWIPO to get notifications of new uploads. Want to listen to TWIPO's past episodes? Visit www.solvingkidscancer.org/podcast

Dr. Evan Noch interviews Dr. Joanna Phillips about her and her team manuscript entitled: "PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications", published online in Neuro-Oncology in March 2022.

Co-hosts Stephanie Winn and Chris Joyce sit down with Dr. Orwa Aboud, a Neuro-Oncologist treating patients with a variety of primary brain tumors such as glioblastoma and low-grade gliomas to discuss advances in treatments as well as signs and symptoms patients should be aware of when it comes to cancers of the brain. To learn more about the UC Davis Comprehensive Cancer Center, visit https://health.ucdavis.edu/cancer.

Over the last year, Cochrane Neuro-Oncology have been publishing a series of new systematic reviews on priority topics for the brain tumour community. These were selected from the most important unanswered questions identified by patients, the public and practitioners. In this podcast, Kathreena Kurian from the University of Bristol in the UK tells us about one of the reviews, which was published in March 2022, looking at the evidence on some of the tests that might help in planning the treatment of patients with a glioma.

Over the last year, Cochrane Neuro-Oncology have been publishing a series of new systematic reviews on priority topics for the brain tumour community. These were selected from the most important unanswered questions identified by patients, the public and practitioners. In this podcast, Kathreena Kurian from the University of Bristol in the UK tells us about one of the reviews, which was published in March 2022, looking at the evidence on some of the tests that might help in planning the treatment of patients with a glioma.

Dr. Ankush Bhatia interviews Dr. Jack Grinband about his recent manuscript entitled "BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas", published online in Neuro-Oncology in July 2021

Dr. Maya Graham interviews Dr. Nduka Amankulor about the recent manuscript entitled: "Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles" published online in Neuro-Oncology in July 2021.

Dr. Maya Graham interviews Dr. Nancy Ann Oberheim Bush about her and her team's paper entitled " Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas" published online in Neuro-Oncology in April 2021

Dr. Iyad Alnahhas interviews Dr. Houton Noushmehr about his recent paper "A serum-based DNA methylation assay provides accurate detection of glioma", published online in Feb 2021 in Neuro-Oncology

Dr. Evan Noch interviews Dr. Jill Barnholtz-Sloan about her recent paper "Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017" published online in Neuro-Oncology in December 2020.

Dr. Iyad Alnahhas talks with Dr. Felix Sahm about his recently published article in Neuro-Oncology entitled: "A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR," published online on November 1, 2020.

Dr. Alireza Mansouri talks with Dr. Lorenzo Bello about his recently published article in Neuro-Oncology entitled: "Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas," published online on October 13, 2020.